Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.8K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

10.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
10.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of basal ganglia regions across murine brain atlases using metadata models and the Waxholm Space.

Scientific data·2024
Same author

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.

BMC cancer·2022
Same author

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.

Acta neuropathologica communications·2019
Same author

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.

Leukemia·2017
Same author

Antinociceptive effect of intrathecally applied alpha<sub>2</sub> agonists (xylazine and detomidine) in sheep and the response to atipamezole.

Veterinary anaesthesia and analgesia·2017
Same author

[Episodic central hypopnea and hypotension : Caused by bleeding into a craniocervical ependymoma].

Der Nervenarzt·2017

Related Experiment Video

Updated: Apr 11, 2026

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
06:20

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor

Published on: January 12, 2024

2.8K

[Primary CNS lymphoma. Progress in the diagnostics and therapy].

A Korfel1, U Schlegel

  • 1Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland, agnieszka.korfel@charite.de.

Der Nervenarzt
|May 28, 2015
PubMed
Summary

Recent advances in primary central nervous system lymphoma (PCNSL) diagnostics show promise, but further validation is needed. Optimal therapy remains undefined, highlighting the need for comparative trials to improve outcomes for this rare, often unfavorable, disease.

More Related Videos

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain
07:45

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain

Published on: March 10, 2026

143
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K

Related Experiment Videos

Last Updated: Apr 11, 2026

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
06:20

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor

Published on: January 12, 2024

2.8K
Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain
07:45

Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain

Published on: March 10, 2026

143
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.7K

Area of Science:

  • Neuro-oncology
  • Hematology
  • Lymphoma research

Context:

  • Primary central nervous system lymphoma (PCNSL) is a rare malignancy.
  • Recent knowledge has expanded regarding PCNSL.
  • Despite advances, PCNSL remains prognostically challenging.

Purpose:

  • To summarize recent progress in PCNSL diagnostics and therapy.
  • To discuss future directions in PCNSL management.
  • To highlight the need for improved diagnostic and therapeutic strategies.

Summary:

  • New cerebrospinal fluid diagnostic methods require validation.
  • Enhanced immunohistological and molecular characterization may reveal new therapeutic targets.
  • The role of whole-brain irradiation post-chemotherapy is uncertain; optimal primary chemotherapy is not established.
  • Future therapies may involve consolidating high-dose methotrexate (HDMTX) with other chemotherapy or stem cell transplantation.
  • Avoiding treatment-related neurotoxicity is a key therapeutic goal.

Impact:

  • Improved diagnostic accuracy for PCNSL.
  • Identification of novel therapeutic targets for PCNSL.
  • Establishment of evidence-based treatment guidelines through comparative trials.
  • Reduced long-term neurotoxicity in PCNSL survivors.